Annals of Pharmacy Practice and Pharmacotherapy
ISSN: 3062-4436
2024, Volume 4, Issue 2, Page No: 125-136

Available online at: www.galaxypub.co/page/journals

Galaxy Publication

Long-Acting Injectables Are Clinical Systems, Not Merely Sustained-Release Products: Depot Evolution, Missed-Dose Recovery, Service Capacity, and Reversibility

David Park[1]*, Elena Rossi[2]

[1]Department of Clinical Pharmacy and Long-Acting Therapeutics, College of Pharmacy, Korea University, Seoul, South Korea.
[2]Department of Pharmaceutical Technology and Long-Acting Injectables, Faculty of Pharmacy, University of Bologna, Bologna, Italy.

***E-mail** ✉ david.park@korea.ac.kr

Received: 26 August 2024; **Revised:** 16 November 2024; **Accepted:** 21 November 2024

ABSTRACT

Long-acting injectable therapies extend pharmacological exposure beyond the administration event, but duration alone does not determine whether treatment remains safe, manageable, or less burdensome. Once a dose has been administered, residual exposure may continue while the patient and clinical service must manage scheduled visits, missed injections, adverse effects, monitoring, switching, and eventual discontinuation. These obligations become particularly important when a depot cannot be removed and exposure cannot be terminated promptly. Evidence from long-acting antiretroviral therapy and prevention, antipsychotics, depot buprenorphine, and longer-duration contraceptive programmes shows that extended dosing intervals can maintain efficacy and reduce administration frequency in selected populations while simultaneously creating product-specific recovery requirements and service dependencies. Missed-dose management is therefore better understood as a recovery problem defined by elapsed time, residual exposure, validated bridging or restart options, monitoring requirements, and access to an administration service. Reversibility is similarly multidimensional: withholding future injections does not eliminate exposure generated by a dose already given. Clinical value consequently depends on compatibility between pharmacokinetic persistence and the operational capacity of the treatment system surrounding it. This Perspective examines the post-administration operating problem and argues that the meaningful unit of evaluation for a long-acting injectable is not only the depot or dosing interval, but the combined product–patient–service configuration required to maintain safe treatment across the entire period of committed exposure.

Keywords: Long-acting injectables, Depot pharmacokinetics, Missed-dose management, Reversibility, Treatment interruption, Service capacity

How to Cite This Article: Park D, Rossi E. Long-Acting Injectables Are Clinical Systems, Not Merely Sustained-Release Products: Depot Evolution, Missed-Dose Recovery, Service Capacity, and Reversibility. Ann Pharm Pract Pharmacother. 2024;4(2):125-36. https://doi.org/10.51847/hbYA5sPVpL

Introduction

Long-acting parenteral drug delivery now spans multiple therapeutic areas and formulation technologies, including polymeric depots, suspensions, lipid-based systems, implants, and other sustained-release platforms intended to maintain drug exposure over weeks or months [1]. Their clinical attraction is readily understood: reducing dosing frequency may lessen the number of administration events needed to sustain treatment. Yet frequency is only one property of a therapeutic regimen. The longer a dose remains pharmacologically active, the longer clinical decisions may continue to be influenced by an administration event that has already occurred.

Formulation science already recognizes that long duration arises from product-specific release processes rather than from a generic injectable property. Poly(lactide-co-glycolide) systems depend on polymer composition, degradation, hydration, drug distribution, and manufacturing attributes that influence release behaviour [2]. Industrial assessments of marketed long-acting products likewise emphasize the interaction among formulation characteristics, administration requirements, patient acceptability, and product-development constraints [3]. The

post-administration clinical question begins once these properties have produced a persistent exposure: what happens when the next administration is late, the product is unavailable, a patient cannot attend the clinic, adverse effects emerge, monitoring is delayed, or treatment needs to be changed before exposure from the previous dose has ended?

Evidence also cautions against assuming that long-acting administration is intrinsically superior to shorter-acting therapy. In schizophrenia, estimates comparing long-acting and oral antipsychotics differ according to whether evidence is derived from randomized trials, cohort studies, or pre-post designs [4]. Such variation indicates that pharmacology, adherence behaviour, patient selection, service organization, and study design jointly influence observed effectiveness.

The distinction becomes especially important when measurable drug persists after treatment has nominally stopped. Long-acting cabotegravir can remain detectable for months after the final administration, with substantial between-person variability [5]. Clinical consensus surrounding long-acting antiretroviral therapy therefore addresses timing, interruption, bridging, monitoring, treatment failure, and discontinuation as regimen-specific management problems [6]. These considerations establish the central question of this Perspective: what clinical-system properties determine whether a long-acting injectable remains safe and workable after administration, particularly when doses are missed, adverse effects emerge, treatment changes, or service capacity is constrained?

The argument is deliberately narrower than a general review of depot engineering. The concern here is not primarily how a formulation creates prolonged release, but what must happen clinically after prolonged release has already been created. A long-acting product commits the patient to a pharmacological trajectory; the clinical system must then remain capable of supporting that trajectory, detecting deviations, and recovering when planned treatment cannot proceed.

Persistence after commitment: Depot release becomes a clinical time horizon

Residual exposure cannot be inferred reliably from the label “long-acting.” PLGA microspheres may display formulation-dependent degradation, diffusion, hydration, erosion, and release behaviour [7]. Lipid-based depots use different physicochemical processes and may vary substantially in how drug leaves the administration site and enters systemic circulation [8]. These distinctions matter clinically because the nominal interval printed on a treatment schedule is not itself a complete description of the exposure trajectory that follows administration.

Experimental formulation work illustrates the point. In an in-situ risperidone implant system, modifications to PLGA molecular weight, lactide:glycolide ratio, and end-group chemistry changed drug-release behaviour and duration [9]. These findings do not establish clinical outcomes, but they demonstrate why two formulations intended for prolonged action cannot be assumed to have interchangeable post-dose behaviour simply because both are described as depots.

Predicting persistence can be difficult even when formulation characteristics are known. Complex injectable products may exhibit multiphasic release in which local depot processes, dissolution, polymer degradation, tissue conditions, and systemic pharmacokinetics interact over time [10]. Development of meaningful in-vitro–in-vivo correlations for long-acting PLGA products therefore requires more than numerical similarity between dissolution and plasma curves. Mechanistic correspondence and validation are critical, and current approaches remain heterogeneous [11]. Formulation attributes, measured release, and validated IVIVC collectively constrain how confidently persistence can be inferred [7, 9, 11].

Clinical translation adds further dependencies. Long-acting delivery systems must connect release performance with dose selection, administration technique, local tolerability, monitoring, product handling, and patient use [12]. From a clinical perspective, the important result is a time horizon of committed exposure. During this period, a previous administration remains relevant even if no new injection occurs.

This time horizon creates an asymmetry absent from many short-acting regimens. Decisions can usually be changed faster than exposure. A clinician may decide immediately to stop future administrations, but the pharmacological consequences of the previous dose may decline slowly. A patient may prefer to switch treatment, but the preceding depot may remain active during the transition. An adverse effect can emerge after administration even though the causative exposure cannot be withdrawn.

Persistence should therefore be represented as a trajectory rather than a categorical product feature. The relevant clinical question is not simply whether a drug is “monthly,” “every two months,” or “every six months.” It is how exposure evolves across the interval, how much remains when planned care is disrupted, and what actions remain available while that exposure persists.

Dosing intervals create appointment obligations

Longer dosing intervals can preserve efficacy when supported by appropriate product evidence and patient selection. In stabilized patients with schizophrenia, a six-month paliperidone palmitate formulation was noninferior to a three-month formulation for relapse prevention during randomized maintenance treatment [13]. The result demonstrates that very infrequent administration can be effective after adequate stabilization. It does not imply that the six-month interval is operationally interchangeable with shorter intervals in every patient or setting.

Long-acting cabotegravir plus rilpivirine provides a particularly informative example because multiple dosing schedules and switching strategies have been studied. Every-two-month administration maintained virologic suppression over extended follow-up compared with monthly administration [14]. Switching virologically suppressed adults from daily oral bictegravir/emtricitabine/tenofovir alafenamide to every-two-month cabotegravir/rilpivirine likewise maintained suppression in the SOLAR trial [15].

The reduction in administration frequency does not eliminate recurrent treatment work. Monthly cabotegravir/rilpivirine maintained HIV suppression relative to oral maintenance therapy, while injection-site reactions and planned injection visits remained part of treatment [16]. Similar findings were observed when long-acting treatment followed oral induction [17]. Every-eight-week administration subsequently demonstrated sustained virologic efficacy, although confirmed virologic failure was not completely eliminated [18]. Longer cabotegravir/rilpivirine maintenance intervals therefore have replicated clinical support [14, 15, 18], but their efficacy remains embedded in an organized programme of recurring administration and follow-up.

A comparable shift in treatment work occurs in other therapeutic areas. Monthly extended-release buprenorphine moves repeated medication administration away from daily patient-controlled dosing and toward periodic health-care-administered depot treatment [19]. In family-planning services, providers and stakeholders considering four- and six-month injectable contraception anticipated fewer visits but continued to identify supply, training, counselling, return planning, side-effect management, and service-access requirements [20].

The dosing interval should consequently be treated as an appointment architecture, not merely a pharmacokinetic descriptor. A planned injection is a point at which several conditions must converge: the patient must be able to attend, the product must be available, appropriately trained personnel must be present, administration must occur correctly, and clinically necessary monitoring or reassessment must be completed.

As intervals become longer, the number of routine administration events may decrease. The operational importance of each event may nevertheless increase because a missed encounter represents a larger disturbance in the intended treatment cycle. Longer intervals can therefore reduce repetitive workload while increasing dependence on the reliability of fewer scheduled encounters.

Table 1. Dosing interval changes the location of treatment work across selected long-acting injectable systems

Therapy configuration	Exposure architecture		Care-delivery workload			Disruption recovery
Long-acting treatment context	**Administration pattern represented in the evidence**	**Residual-exposure implication**	**Main administration setting**	**Continuing clinical requirement**	**Operational effect of longer interval**	**Recovery implication after disruption**
PLGA-based long-acting products	Weeks to months, product dependent	Release may continue through polymer degradation, diffusion, or erosion	Clinical injection setting	Product- and indication-specific follow-up	Fewer administrations do not remove formulation-dependent persistence	Recovery cannot be inferred from nominal interval alone
Paliperidone palmitate maintenance	Three- or six-month maintenance after stabilization	Therapeutic exposure intentionally extends across prolonged maintenance	Health-care administration	Psychiatric assessment and relapse surveillance	Very infrequent dosing is feasible in selected stable patients	Late administration must follow product-specific re-initiation logic
Cabotegravir/rilpivirine maintenance	Monthly or every two months	Depot exposure persists between injections and after discontinuation	Recurrent clinical injection visits	Virologic monitoring and management of interruption or failure	Daily oral dosing becomes fewer but time-sensitive injection encounters	Recovery may require delayed dosing, bridging, reloading, restart, or switching depending on the

						product-specific situation
Extended-release buprenorphine	Monthly depot administration	Sustained exposure continues between supervised injections	Qualified health-care setting	OUD follow-up and safety assessment	Daily dosing work shifts toward periodic provider delivery	Missed administration increases dependence on access to the treatment service
Longer-duration injectable contraception	Extended intervals beyond conventional injectable schedules	Contraceptive exposure persists across larger intervals	Family-planning service or trained provider	Counselling, side-effect management, return planning	Contact frequency may fall while each scheduled return remains operationally important	Delivery design must preserve reliable return and product availability

Missed doses create recovery problems defined by residual exposure and restart design

A missed injection is not pharmacologically equivalent to abruptly stopping an oral medication. After a long-acting dose, drug may continue entering the circulation even after the planned administration date has passed. Follow-up from long-acting cabotegravir prevention studies illustrates why this distinction matters: interpretation of breakthrough infection depends on whether injections were received on schedule, delayed, discontinued, or followed by residual exposure [21].

Breakthrough infections themselves occurred under heterogeneous exposure conditions. HPTN 084 characterized infections that arose with different relationships to cabotegravir dosing, including circumstances involving delayed administration or limited recent exposure [22]. The parent trial nevertheless demonstrated strong preventive efficacy under a programme with high injection coverage [23]. HPTN 083 similarly demonstrated superior overall prevention efficacy while identifying delayed diagnosis and resistance-related concerns in a small number of infections occurring around long-acting exposure [24].

These observations make a binary “adherent/nonadherent” interpretation inadequate. A late injection can occur while exposure remains substantial, while exposure is declining through a potentially important range, or after prior exposure has become negligible. Those states cannot be assumed to require identical clinical actions.

Recovery may also require more than simply administering the missed injection at the next available opportunity. Updated recommendations concerning cabotegravir/rilpivirine in selected patients with adherence challenges emphasize the importance of intensive follow-up and clinical support under specific circumstances [25]. The ability to recover from an interruption therefore depends partly on whether the service can recognize the missed encounter, reach the patient, determine the timing and clinical context, perform relevant monitoring, and deliver the appropriate subsequent treatment.

Even the language used for treatment interruption needs operational precision. An international survey and Delphi process addressing cabotegravir/rilpivirine identified sufficient variation in definitions of virologic failure and discontinuation to justify development of shared terminology [26]. These definitions are regimen specific, but they demonstrate why a delayed dose, an interruption, repeated missed administrations, treatment failure, and permanent discontinuation should not be treated as synonymous events.

The practical implication is that missed-dose management should be conceptualized as recovery from a disturbed exposure trajectory. The calendar delay identifies when planned treatment diverged from schedule; it does not by itself define what the patient needs next.

Table 2. Interruption states require different recovery logic because residual exposure and rescue options are product specific

Interruption and exposure state		**Recovery decision**			**Safety evidence**	
Interruption state	**Residual-exposure question**	**Immediate clinical question**	**Potential recovery mode**	**Possible role of bridging**	**Monitoring concern**	**Evidence required before action**
Administration remains within supported scheduling flexibility	Is intended exposure likely to remain adequate?	Can the planned injection be given without reconstructing the regimen?	Continue the supported injection sequence	Usually unnecessary unless specified	Routine indication-specific monitoring	Product-specific dosing guidance

Administration is materially delayed but previous depot exposure remains	How much clinically relevant exposure may remain?	Is delayed administration sufficient or is re-initiation needed?	Delayed dose, reload, or restart where supported	May be relevant when a validated bridge exists	Consequences of declining or uncertain exposure	Product-specific PK, trial, and clinical-management evidence
Multiple planned administrations are missed	Has the patient moved from a delayed dose into treatment interruption?	Is previous treatment still recoverable, or should therapy be reconstructed?	Re-initiation, reassessment, alternative treatment, or product-specific bridge	Potentially important where validated	Disease recurrence, treatment failure, withdrawal, or resistance depending on indication	Product-specific interruption evidence
Patient chooses to stop future injections	How long will previously administered drug remain active?	What risks continue despite withholding future doses?	Tail monitoring and transition planning	Alternative therapy may need to start during residual exposure	Adverse effects, recurrence, resistance, interactions, or diagnostic effects depending on drug	Tail pharmacokinetics and indication-specific guidance
Apparent treatment failure occurs despite apparently correct timing	Was the problem exposure, administration, biology, resistance, or another mechanism?	Is the event actually attributable to scheduling?	Diagnostic reassessment before assuming a missed-dose mechanism	Depends on subsequent treatment	Failure mechanism must be established where possible	Clinical, laboratory, PK, and product-specific evidence

No universal missed-dose algorithm follows from these states. The same number of days beyond a scheduled appointment can represent different pharmacological circumstances for different products. A defensible recovery strategy therefore depends on at least four linked considerations: elapsed time, residual exposure from prior dosing, the availability of a validated bridge or re-initiation strategy, and the monitoring required to identify treatment failure or harm.

The missed appointment is an event. Recoverability is a state produced by the interaction between the product, the remaining exposure, the patient's clinical condition, and the capabilities of the service attempting to restore treatment.

Reversibility and switching after a dose that cannot be withdrawn

Long-acting therapies are sometimes described as reversible because future administrations can be stopped. This obscures an important clinical distinction. Treatment-policy reversibility is the ability to decide not to administer another dose. Pharmacological reversibility is the ability to terminate exposure created by a dose already given. These two properties may differ substantially.

Cabotegravir tail pharmacokinetics provide a clear example: future injections can be withheld immediately, but residual drug may persist for a prolonged period [5]. Other long-acting technologies differ in their exact persistence, and formulation evidence should not be used to assign one common tail duration across products.

Switching treatment therefore modifies the future regimen without necessarily eliminating the contribution of the previous depot. Trials of cabotegravir/rilpivirine establish that selected patients can move from oral therapy to long-acting maintenance and can be treated successfully under different injection intervals [15]. Those results support planned switching into long-acting treatment, but they do not imply that the pharmacological effect of a preceding long-acting dose disappears when another therapeutic decision is made.

Persistent exposure can also change how subsequent clinical events are interpreted. In cabotegravir PrEP, residual exposure during incident HIV infection can modify early virologic and diagnostic behaviour [27]. Such effects are specific to antiretroviral pharmacology and should not be generalized mechanically to antipsychotics, buprenorphine, or contraceptives. They nevertheless demonstrate the broader principle that persistent exposure can continue influencing clinical interpretation after the decision to discontinue further injections.

Reversibility is therefore multidimensional. It includes whether a depot can be physically removed, how quickly exposure declines, whether adverse effects can be mitigated while drug remains present, whether monitoring can detect emerging harm, and whether another treatment can be initiated safely before the previous agent has disappeared.

This distinction is particularly important when adverse effects arise. With a short-acting oral medicine, withholding subsequent doses may rapidly reduce additional exposure. With a depot injection, stopping future administrations may be clinically correct while leaving the patient exposed to drug continuing to leave the administration site. Clinical management may still include symptomatic treatment, monitoring, escalation, or switching, but it occurs under the constraint that the original dose cannot simply be recalled.

Safe long-acting treatment therefore requires more than confidence that the product can maintain exposure. It requires a credible plan for what can be done during the period in which exposure cannot be rapidly terminated.

Administration capacity and monitoring become regimen components

A long-acting regimen may remain pharmacologically active even when its clinical delivery system becomes temporarily ineffective. Implementation studies of cabotegravir/rilpivirine illustrate the practical distinction. In European centres participating in CARISEL, successful delivery was supported by advance planning, staff education, injection training, scheduling, and workflow adaptation [28]. These are not formulation attributes, yet they determine whether the formulation can be used as intended.

Structural constraints may influence whether these functions are consistently available. US clinics preparing long-acting antiretroviral programmes reported staffing, reimbursement, resource, and implementation barriers that could restrict equitable delivery [29]. A long-acting medicine can therefore be pharmacologically suitable while remaining difficult to use in a setting that cannot reliably procure, schedule, administer, and follow it.

The patient's experience adds another level. Early adopters of cabotegravir/rilpivirine described benefits such as privacy and relief from daily tablets, alongside injection pain, recurrent appointments, and practical burdens associated with continuing treatment [30]. A regimen may therefore reduce one form of treatment work while creating another.

Contemporary HIV recommendations similarly place long-acting therapy within a broader clinical-management system that includes monitoring, access, switching, and follow-up [31]. These functions become especially important after deviation from the ideal schedule. The service must determine whether the patient is simply late, has entered a product-defined interruption state, requires bridging or re-initiation, or needs another treatment strategy.

Real-world experience suggests that long-acting therapy can also be delivered to clinically more complicated populations under appropriately structured care. Observational evidence has described viral suppression among patients initiating long-acting antiretroviral treatment with and without baseline viraemia [32]. Because these data are nonrandomized, they cannot isolate the causal contribution of service intensity. They nevertheless make an important hypothesis plausible: routine performance may depend on synchronization among pharmacological efficacy, clinical selection, appointment systems, monitoring, outreach, and recovery.

Figure 1 places these relationships within the post-administration time horizon.



Figure 1. Clinical workability of a long-acting injectable depends on the overlap between persistent exposure and service capacity

Access and treatment burden determine whether long duration remains workable

Lower administration frequency can reduce one dimension of treatment burden without reducing all of them. Patients receiving cabotegravir/rilpivirine have described relief from daily pill taking and greater privacy while also reporting injection discomfort, recurrent appointments, and practical burdens surrounding attendance [30]. The net effect is therefore individual and contextual.

Provider-administered depot buprenorphine illustrates how long-acting treatment can redistribute adherence work. Daily medication-taking responsibilities are partly replaced by the requirement to reach a qualified treatment service for scheduled injections [19]. Longer-duration injectable contraception raises a similar issue in another domain: fewer administrations may reduce routine visit frequency, but counselling, supply continuity, side-effect management, and return planning remain relevant [20].

Psychiatric evidence provides an additional test of the assumption that longer exposure is automatically superior. Nationwide observational data suggest that several long-acting antipsychotic strategies perform strongly in routine care [33]. Network meta-analysis confirms relapse-prevention benefits for multiple long-acting agents while also showing differences in acceptability and evidentiary certainty [34]. A broader comparison of oral and long-acting antipsychotics indicates that many direct efficacy comparisons are relatively close, increasing the importance of tolerability and treatment fit [35]. Psychiatric evidence therefore shows that clinical performance cannot be reduced to formulation duration alone [33-35].

Resource availability further constrains transferability. The WHO Mental Health Gap Action Programme guideline update explicitly incorporates feasibility, resources, values, and setting when moving from evidence to recommendations [36]. These considerations do not change the molecule or depot, but they alter whether a treatment strategy can be executed safely and sustainably.

The principal operational risks are summarized in **Table 3**.

Table 3. Reversibility and operational risks arise at different points after a long-acting dose has been committed

Clinical-system problem	What remains committed after injection	What can still be changed	Service capability required	Principal patient or safety concern	Applicability boundary
Committed exposure and therapeutic change					
Adverse effect after administration	Previous depot and continued release	Symptom management, monitoring, future dosing, switching	Timely assessment and access to alternative management	Exposure may persist after the decision to stop future doses	Persistence and toxicity are product specific
Patient wishes to discontinue	Residual exposure from prior injection	Future injections and subsequent treatment strategy	Counselling, monitoring, transition planning	Preference change does not terminate exposure immediately	Tail duration differs among products
Another therapy becomes necessary	Some prior drug may remain active	Choice and timing of subsequent therapy	Medication review and product-specific switching plan	Overlap, interaction, or delayed loss of prior effect may matter	Switching evidence is indication and product specific
Administration continuity					
Scheduled injection is missed	Residual exposure from preceding dose	Recovery timing, bridging, restart, alternative treatment	Tracking, outreach, reassessment, administration	Declining or uncertain exposure may create treatment risk	No universal missed-dose threshold exists
Clinic cannot provide scheduled administration	Previous exposure may continue despite service interruption	Relocation, bridge, delayed restart where validated	Procurement, staffing, administration coordination	Pharmacological persistence can outlast operational availability	Consequence depends on product, indication, and delay
Care capacity and causal attribution					
Patient cannot reliably reach the service	Previous depot remains active after each successful administration	Delivery location, scheduling support, future regimen	Accessible services and continuity mechanisms	Fewer injections may still impose travel, cost, time, or logistical burden	Longer interval does not guarantee lower overall burden
Apparent failure despite correct administration	Previously administered drug remains present	Diagnostic reassessment and subsequent treatment	Monitoring, laboratory support, specialist review where needed	Incorrect attribution to nonadherence may obscure another failure mechanism	Failure mechanisms differ across products and diseases

Discussion and translational implications

The evidence supports a conditional version of the article's central proposition. Long-acting injectables become clinical systems because prolonged exposure creates obligations extending beyond the injection itself. Pharmacokinetic persistence, scheduled administration, monitoring, interruption management, switching, and access remain connected throughout the period in which a previous dose remains active.

This does not mean that every long-acting therapy requires the same infrastructure. The evidence is strongest for particular product–indication combinations. Cabotegravir provides unusually rich information concerning residual exposure, injection timing, interruption, diagnostic consequences, resistance, and service implementation. Antipsychotics provide complementary evidence concerning long maintenance intervals, relapse prevention, real-world effectiveness, and tolerability. Buprenorphine and contraceptive programmes demonstrate that long duration can redistribute responsibility between patients and services. The shared principle is operational; the detailed recovery rules remain product specific.

Three discriminating propositions follow.

First, the consequence of a missed administration should depend on the interaction between elapsed time and residual exposure when recovery is attempted. A missed appointment is therefore expected to have different implications when substantial effective exposure remains, when exposure is declining through a clinically consequential range, and when prior exposure is negligible. This proposition would be weakened if clinically meaningful recovery requirements proved unrelated to residual exposure after appropriate adjustment for disease and patient characteristics.

Second, extending the interval between administrations should reduce net treatment burden only when the benefit of fewer routine dosing events is not offset by travel, appointment coordination, injection discomfort, monitoring, access barriers, or recovery work. This proposition can be tested by measuring total patient and service workload rather than using administration frequency as its surrogate.

Third, products with similar pharmacological efficacy may produce different routine outcomes when service synchronization differs. Appointment tracking, product availability, trained administration, monitoring, outreach after missed visits, and access to recovery pathways are plausible moderators of real-world performance. Comparative implementation research could test whether variation in these functions predicts on-time administration, continuation, treatment failure, or discontinuation after accounting for patient and disease characteristics.

These propositions also alter what should be considered during development of future long-acting products. Demonstrating prolonged release and acceptable average exposure is essential but incomplete. Clinically informative development should also characterize the consequences of delayed administration, the shape and variability of residual exposure, feasible recovery pathways, the conditions under which bridging or re-initiation is validated, monitoring requirements during persistent exposure, and the practical infrastructure required to administer the treatment reliably.

The relationship among these elements is summarized in **Figure 2**.



Figure 2. Recovery after disruption depends on residual exposure, clinical state, and the remaining degrees of therapeutic freedom

Conclusion

Long-acting injectables can reduce dosing frequency and maintain effective treatment across several therapeutic areas, but duration alone does not determine whether they remain safe or workable after administration. Clinical manageability depends on the relationship between persistent exposure and the surrounding capacity to deliver scheduled care, identify disruptions, monitor emerging problems, recover missed doses, manage adverse effects, and transition to another therapy when necessary.

The meaningful advantage of long duration is therefore conditional. It is greatest when reduced administration frequency is accompanied by reliable clinical infrastructure and clearly characterized recovery pathways throughout the period in which the previous dose remains pharmacologically active. A long-acting injectable is consequently best evaluated not only as a sustained-release product, but as a treatment whose pharmacology and clinical operating system must remain compatible for the entire duration of committed exposure.

Acknowledgments: None

Conflict of Interest: None

Financial Support: None

Ethics Statement: None

References

1. Jindal AB, Bhide AR, Salave S, Rana D, Benival D. Long-acting parenteral drug delivery systems for the treatment of chronic diseases. Adv Drug Deliv Rev. 2023;198:114862. doi:10.1016/j.addr.2023.114862
2. Park K. PLGA-based long-acting injectable (LAI) formulations. J Control Release. 2025;382:113758. doi:10.1016/j.jconrel.2025.113758
3. Alidori S, Subramanian R, Holm R. Patient-centric long-acting injectable and implantable platforms—an industrial perspective. Mol Pharm. 2024;21(9):4238-58. doi:10.1021/acs.molpharmaceut.4c00665
4. Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: A systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387-404. doi:10.1016/S2215-0366(21)00039-0
5. Landovitz RJ, Li S, Eron JJ Jr, Grinsztejn B, Dawood H, Liu AY, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: A secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472-81. doi:10.1016/S2352-3018(20)30106-5
6. Sherman EM, Agwu AL, Ambrosioni J, Behrens GMN, Chu C, Collins LF, et al. Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2024;44(7):494-538. doi:10.1002/phar.2922
7. Wan B, Bao Q, Burgess DJ. Long-acting PLGA microspheres: Advances in excipient and product analysis toward improved product understanding. Adv Drug Deliv Rev. 2023;198:114857. doi:10.1016/j.addr.2023.114857
8. Sharma R, Yadav S, Yadav V, Akhtar J, Katari O, Kuche K, et al. Recent advances in lipid-based long-acting injectable depot formulations. Adv Drug Deliv Rev. 2023;199:114901. doi:10.1016/j.addr.2023.114901
9. Wang X, Bao Q, Wang R, Kwok O, Maurus K, Wang Y, et al. In situ forming risperidone implants: Effect of PLGA attributes on product performance. J Control Release. 2023;361:777-91. doi:10.1016/j.jconrel.2023.08.029
10. Dabke A, Ghosh S, Dabke P, Sawant K, Khopade A. Revisiting the in-vitro and in-vivo considerations for in-silico modelling of complex injectable drug products. J Control Release. 2023;360:185-211. doi:10.1016/j.jconrel.2023.06.029
11. Wang Y, Otte A, Park H, Park K. In vitro-in vivo correlation (IVIVC) development for long-acting injectable drug products based on poly(lactide-co-glycolide). J Control Release. 2025;377:186-96. doi:10.1016/j.jconrel.2024.11.021
12. Li W, Tang J, Lee D, Tice TR, Schwendeman SP, Prausnitz MR. Clinical translation of long-acting drug delivery formulations. Nat Rev Mater. 2022;7(5):406-20. doi:10.1038/s41578-021-00405-w
13. Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ,. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25(3):238-51. doi:10.1093/ijnp/pyab071
14. Overton ET, Richmond G, Rizzardini G, Thalme A, Girard PM, Wong A, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis. 2023;76(9):1646-54. doi:10.1093/cid/ciad020
15. Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): A randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):e566-77. doi:10.1016/S2352-3018(23)00136-4

16. Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112-23. doi:10.1056/NEJMoa1904398
17. Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124-35. doi:10.1056/NEJMoa1909512
18. Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: A randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV. 2021;8(11):e679-89. doi:10.1016/S2352-3018(21)00185-5
19. Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393(10173):778-90. doi:10.1016/S0140-6736(18)32259-1
20. Callahan RL, Burke HM, Lawton A, OlaOlorun FM, Mubiru F, Anyasi H, et al. Service delivery considerations for introducing new injectable contraceptives lasting 4 and 6 months in Nigeria and Uganda: A qualitative study. Glob Health Sci Pract. 2023;11(6):e2300214. doi:10.9745/GHSP-D-23-00214
21. Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, et al. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: A secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. Lancet HIV. 2023;10(12):e767-78. doi:10.1016/S2352-3018(23)00261-8
22. Eshleman SH, Fogel JM, Piwowar-Manning E, Chau G, Cummings V, Agyei Y, et al. Characterization of human immunodeficiency virus infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate/emtricitabine for HIV prevention: HPTN 084. J Infect Dis. 2022;225(10):1741-9. doi:10.1093/infdis/jiab576
23. Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: Results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-89. doi:10.1016/S0140-6736(22)00538-4
24. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595-608. doi:10.1056/NEJMoa2101016
25. Sax PE, Thompson MA, Saag MS; IAS-USA Treatment Guidelines Panel. Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA Guidelines Panel. JAMA. 2024;331(12):1060-1. doi:10.1001/jama.2024.2985
26. Orkin C, Paterson A, Elias A, Smuk M, Ring K, Volny-Anne A, et al. Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): An international survey and Delphi process. Lancet HIV. 2025;12(9):e649-59. doi:10.1016/S2352-3018(25)00131-6
27. Landovitz RJ, Delany-Moretlwe S, Fogel JM, Marzinke MA, Piwowar-Manning E, Richardson P, et al. Features of HIV infection in the context of long-acting cabotegravir preexposure prophylaxis. N Engl J Med. 2024;391(13):1253-6. doi:10.1056/NEJMc2402088
28. Gutner CA, Hocqueloux L, Jonsson-Oldenbüttel C, Vandekerckhove L, van Welzen BJ, Slama L, et al. Implementation of long-acting cabotegravir and rilpivirine: Primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations. J Int AIDS Soc. 2024;27(7):e26243. doi:10.1002/jia2.26243
29. Nguyen N, Lane B, Golub SA, Chastain C, Zucker J, King K, et al. Long-acting injectable ART to advance health equity: A descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP Project. J Int AIDS Soc. 2024;27(Suppl 1):e26282. doi:10.1002/jia2.26282
30. Christopoulos KA, Smith MB, Pareek P, Dawdani A, Erguera XA, Dance KV, et al. Learning from the first: A qualitative study of the psychosocial benefits and treatment burdens of long-acting cabotegravir/rilpivirine among early adopters in three U.S. clinics. J Int AIDS Soc. 2024;27(11):e26394. doi:10.1002/jia2.26394

31. Gandhi RT, Landovitz RJ, Sax PE, Smith DM, Springer SA, Günthard HF, et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel. JAMA. 2025;333(7):609-28. doi:10.1001/jama.2024.24543
32. Spinelli MA, Heise MJ, Gistand N, Cox C, Grochowski J, Oskarsson J, et al. HIV viral suppression with use of long-acting antiretroviral therapy in people with and without initial viremia. JAMA. 2025;333(16):1451-3. doi:10.1001/jama.2025.0109
33. Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686-93. doi:10.1001/jamapsychiatry.2017.1322
34. Ostuzzi G, Bertolini F, Del Giovane C, Tedeschi F, Bovo C, Gastaldon C, et al. Maintenance treatment with long-acting injectable antipsychotics for people with nonaffective psychoses: A network meta-analysis. Am J Psychiatry. 2021;178(5):424-36. doi:10.1176/appi.ajp.2020.20071120
35. Schneider-Thoma J, Chalkou K, Dörries C, Bighelli I, Ceraso A, Huhn M, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: A systematic review and network meta-analysis. Lancet. 2022;399(10327):824-36. doi:10.1016/S0140-6736(21)01997-8
36. Lorenz C, Bighelli I, Hanna F, Akhtar A, Leucht S. Update of the World Health Organization's Mental Health Gap Action Programme Guideline for psychoses (including schizophrenia). Schizophr Bull. 2024;50(6):1310-25. doi:10.1093/schbul/sbae043